Journal
MOLECULAR CELL
Volume 60, Issue 6, Pages 847-859Publisher
CELL PRESS
DOI: 10.1016/j.molcel.2015.10.033
Keywords
-
Categories
Funding
- Cold Spring Harbor Laboratory NCI Cancer Center Support grant [CA455087]
- Alex's Lemonade Stand Foundation
- V Foundation
- Martin Sass Foundation
- Lauri Strauss Leukemia Foundation
- Cold Spring Harbor Laboratory Women in Science Award
- Burroughs-Wellcome Fund Career Award
- NIH grant [NCI RO1 CA174793]
- Leukemia & Lymphoma Society Scholar Award
- Boehringer Ingelheim
Ask authors/readers for more resources
The bromodomain and extraterminal (BET) protein BRD4 is a therapeutic target in acute myeloid leukemia (AML). Here, we demonstrate that the AML maintenance function of BRD4 requires its interaction with NSD3, which belongs to a subfamily of H3K36 methyltransferases. Unexpectedly, AML cells were found to only require a short isoform of NSD3 that lacks the methyltransferase domain. We show that NSD3-short is an adaptor protein that sustains leukemia by linking BRD4 to the CHD8 chromatin remodeler, by using a PWWP chromatin reader module, and by employing an acidic transactivation domain. Genetic targeting of NSD3 or CHD8 mimics the phenotypic and transcriptional effects of BRD4 inhibition. Furthermore, BRD4, NSD3, and CHD8 colocalize across the AML genome, and each is released from super-enhancer regions upon chemical inhibition of BET bromodomains. These findings suggest that BET inhibitors exert therapeutic effects in leukemia by evicting BRD4-NSD3-CHD8 complexes from chromatin to suppress transcription.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available